← Search & browse all drugs
RESPIRATORY SYSTEM › DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES › OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES › Other systemic drugs for obstructive airway diseases
seratrodast
R03DX06
Adult Dosing
- Bronchial asthma: 80 mg orally twice daily after meals
Pediatric Dosing
- Safety and efficacy in pediatric patients have not been established
Mechanism of Action
- Selective thromboxane A2 (TXA2) receptor antagonist
- Inhibits TXA2-induced bronchoconstriction, airway hyperresponsiveness, and inflammation
Contraindications
- Hypersensitivity to seratrodast or any component of the formulation
- Severe liver dysfunction
Adverse Reactions
- Elevated liver enzymes (AST, ALT)
- Gastric discomfort, nausea, abdominal pain
- Diarrhea
- Headache
- Palpitations
Drug Interactions
- Metabolized primarily by CYP2C9 and CYP3A4; potential interactions with inhibitors or inducers of these enzymes
- No major clinically significant pharmacokinetic drug interactions established, but monitor closely with hepatotoxic drugs
Curated Content: Needs Vetting Before Put to Clinical Use